Gilead Misses Full-Year EPS Guidance, Stock Drops 4.5% Despite Q4 Revenue Beat
Summary
Gilead Sciences reported Q4 revenue of $7.93 billion, which was up 4.7% year-over-year and approximately 3.2% above analyst estimates. However, the company missed its full-year EPS guidance, leading to a 4.5% decline in its stock price. This earnings report provides new financial performance data following a period of significant M&A activity for Gilead, including recent acquisitions and tender offers. The EPS miss and negative stock reaction are material for traders, despite the revenue beat, indicating investor focus on profitability and future guidance. Citigroup maintained a Buy rating and raised its price target to $165, suggesting a more optimistic long-term view despite the immediate earnings disappointment.
At the time of this announcement, GILD was trading at $138.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $172.6B. The 52-week trading range was $93.37 to $157.29. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.